Pro-life group says Trump admin didn't give key abortion drug commitments before Overton FDA nomination pulled

Susan B. Anthony Pro-Life America opposed Heidi Overton's FDA confirmation until the Trump administration committed to ending mail-order abortion drugs.
Pro-life group says Trump admin didn't give key abortion drug commitments before Overton FDA nomination pulled

A leading pro-life group, Susan B. Anthony Pro-Life America, opposed Heidi Overton’s nomination to lead the FDA, seeking commitments from the Trump administration to end mail-order access to abortion drugs and to revise the safety study of mifepristone. The White House withdrew Overton’s nomination amid Senate confirmation questions, with Senator Bill Cassidy disputing the claim of insufficient votes. The pro-life group argues the administration has the authority to enact policy changes without waiting for an FDA commissioner.

  • A pro-life group asked the Senate to delay Heidi Overton’s FDA nomination until the Trump administration committed to ending mail-order abortion drugs.
  • The group also wants the FDA to change how it studies the safety of abortion pills, citing flaws in the current methodology.
  • The White House withdrew Overton’s nomination due to a lack of Senate support.
  • Senator Bill Cassidy stated he believed Overton had sufficient votes for confirmation.
  • The pro-life group asserts the administration can implement policy changes immediately without an appointed FDA commissioner.
Write a comment